Opinion
Video
Author(s):
Panelists discuss how biosimilar manufacturers offer both high-wholesale acquisition cost (WAC) and low-WAC product versions to navigate complex reimbursement landscapes, sharing their experiences with low-WAC options on formularies, defining private label agreements as strategies to improve biosimilar access across different patient populations, and examining the rationale behind PBMs' (pharmacy benefit managers) implementation of these agreements, including their specific components and benefits.
Biosimilars Pricing Strategies and Private Label Agreements: A Summary for Physicians
Dual Pricing Strategies for Biosimilars
Manufacturers of biosimilars often offer both high-WAC and low-WAC versions of their products for several strategic reasons, including the following:
Institutional Experience With Low-WAC Biosimilars
Health care institutions implementing low-WAC biosimilars on formulary have observed the following:
Private Label Agreements: Definition and Benefits
Private label agreements are specialized contractual arrangements in which:
PBM Implementation of Private Label Agreements
PBMs are increasingly utilizing private label agreements for biosimilars due to the following: